TY - JOUR
T1 - Referral care paths for non-alcoholic fatty liver disease—Gearing up for an ever more prevalent and severe liver disease
AU - van Dijk, Anne-Marieke
AU - Schattenberg, J. rn M.
AU - Holleboom, Adriaan G.
AU - Tushuizen, Maarten E.
N1 - Funding Information: We thank Stijn Crobach for providing the histology images. Adriaan G. Holleboom was supported by the Amsterdam UMC Fellowship grant, a Holland Health TKI-PPP grant and by research grants from Gilead and Novo Nordisk. Funding Information: We thank Stijn Crobach for providing the histology images. Adriaan G. Holleboom was supported by the Amsterdam UMC Fellowship grant, a Holland Health TKI‐PPP grant and by research grants from Gilead and Novo Nordisk. Publisher Copyright: © 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent and potentially severe liver disease, emphasizing the need for implementation of widely supported care paths for patients at risk for advanced stages of NAFLD. In particular, the distinction of patients with a progressive and/or advanced, fibrotic NAFLD from those with simple steatosis requires improvement, as well as the awareness for NAFLD among health care professionals. Broad acceptance and implementation of interdisciplinary care paths in the near future will bring enhanced identification of those patients that benefit from surveillance, intensive lifestyle management, and empirical or investigational pharmacotherapy and enhance our epidemiological grasp of NAFLD in relation to lifestyle, genetic background, and cardiometabolic comorbidities related to NAFLD.
AB - Non-alcoholic fatty liver disease (NAFLD) is an increasingly prevalent and potentially severe liver disease, emphasizing the need for implementation of widely supported care paths for patients at risk for advanced stages of NAFLD. In particular, the distinction of patients with a progressive and/or advanced, fibrotic NAFLD from those with simple steatosis requires improvement, as well as the awareness for NAFLD among health care professionals. Broad acceptance and implementation of interdisciplinary care paths in the near future will bring enhanced identification of those patients that benefit from surveillance, intensive lifestyle management, and empirical or investigational pharmacotherapy and enhance our epidemiological grasp of NAFLD in relation to lifestyle, genetic background, and cardiometabolic comorbidities related to NAFLD.
KW - care path
KW - guideline
KW - hepatology
KW - liver fibrosis
KW - non-alcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85116318004&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/ueg2.12150
DO - https://doi.org/10.1002/ueg2.12150
M3 - Review article
C2 - 34609086
SN - 2050-6406
VL - 9
SP - 903
EP - 909
JO - United European gastroenterology journal
JF - United European gastroenterology journal
IS - 8
ER -